SEC Tracker
Get the app

Adaptin Bio APTN

Adaptin Bio Q2 FY25: net loss $1.5M; diluted EPS −$0.18

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Adaptin Bio reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$1.5MAgainst −$36K in Q2 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.18Against −$0.01 in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$1.4M+419626% from $322 in Q2 FY2410-Q balance sheet, on EDGAR
  4. Cash from operations−$1.0M−1855% from $58K in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Adaptin Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Artelo Biosciences ARTL public float $9M, Jun 30, 2025
  2. Bioxytran BIXT public float $9M, Jun 30, 2025
  3. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  4. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  5. TherapeuticsMD TXMD public float $9M, Jun 30, 2025